Gotham Asset Management LLC Acquires 4,002 Shares of Zoetis Inc. (NYSE:ZTS)

Gotham Asset Management LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 100.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 7,973 shares of the company's stock after purchasing an additional 4,002 shares during the quarter. Gotham Asset Management LLC's holdings in Zoetis were worth $1,299,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. JPMorgan Chase & Co. raised its holdings in shares of Zoetis by 10.6% during the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company's stock worth $569,834,000 after acquiring an additional 279,092 shares during the period. Miracle Mile Advisors LLC bought a new position in Zoetis during the 4th quarter worth about $272,000. Park Avenue Securities LLC raised its stake in shares of Zoetis by 4.3% in the 4th quarter. Park Avenue Securities LLC now owns 24,148 shares of the company's stock valued at $3,934,000 after purchasing an additional 997 shares during the period. Burney Co. raised its stake in shares of Zoetis by 15.2% in the 4th quarter. Burney Co. now owns 4,749 shares of the company's stock valued at $774,000 after purchasing an additional 627 shares during the period. Finally, Werlinich Asset Management LLC lifted its holdings in shares of Zoetis by 3.8% in the fourth quarter. Werlinich Asset Management LLC now owns 2,198 shares of the company's stock valued at $357,000 after purchasing an additional 80 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

Shares of ZTS traded down $0.31 during midday trading on Tuesday, reaching $163.63. The stock had a trading volume of 1,780,660 shares, compared to its average volume of 2,511,333. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The firm has a market cap of $72.85 billion, a PE ratio of 29.91, a P/E/G ratio of 2.78 and a beta of 0.94. The firm has a 50 day simple moving average of $156.51 and a 200-day simple moving average of $165.09. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same quarter in the prior year, the company earned $1.38 earnings per share. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares of the company's stock, valued at approximately $2,682,770. This trade represents a 2.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ZTS shares. UBS Group dropped their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Stifel Nicolaus reduced their target price on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. Barclays lifted their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, Piper Sandler increased their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $212.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.